Quantcast

Latest Alimera Sciences Inc. Stories

2014-10-09 08:27:53

CEO to Discuss Milestone FDA Approval of ILUVIEN as the First Long-Term Treatment for Diabetic Macular Edema ATLANTA, Oct. 9, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it will present at the Ophthalmology Innovation Summit (OIS) at the American Academy of Ophthalmology (AAO) annual meeting in Chicago,...

2014-09-30 16:28:04

Growth Capital Allows Alimera to Fulfill Its Milestone Obligation Triggered by FDA Approval of ILUVIEN® ATLANTA, Sept. 30, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has received a $25 million advance from Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (Hercules). The payment is the second...

2014-09-29 08:30:12

A single ILUVIEN implant provides treatment for three years ATLANTA, Sept. 29, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will hold a conference call to provide additional information regarding the recent approval by the U.S. Food and Drug Administration (FDA) of ILUVIEN(®) for the treatment of...

2014-09-26 16:23:57

Company will issue a more detailed announcement on Monday, September 29 ATLANTA, Sept. 26, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has approved ILUVIEN(®) for the treatment of diabetic macular edema (DME) in patients who have been previously treated...

2014-09-03 08:33:15

Sweden is latest country to grant marketing authorization ATLANTA, Sept. 3, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Swedish Medical Products Agency has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME)...

2014-08-07 16:29:18

ILUVIEN® Injections Increased over 25% in the United Kingdom on Sequential Basis from First Quarter 2014 ATLANTA, Aug. 7, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the second quarter ended June 30, 2014. "We achieved an important milestone during the second quarter of 2014 as...

2014-07-31 16:28:25

ATLANTA, July 31, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Danish Health and Medicines Authority has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available...

2014-07-28 16:26:45

Portugal approves reimbursement for ILUVIEN ATLANTA, July 28, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Norwegian Medicines Evaluation Board has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered...

2014-07-24 16:26:33

ATLANTA, July 24, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its second quarter of fiscal year 2014 financial results after the market close on Thursday, August 7, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET. The conference call will be hosted by...

2014-06-30 08:29:57

ATLANTA, June 30, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the positive outcome of the Repeat-Use Procedure for ILUVIEN® for the treatment of chronic diabetic macular edema (DME) in an additional 10 European Union countries. Alimera submitted the application through the Mutual Recognition Procedure...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.